Pricing Log in Create free account

Genelux Corporation (GNLX) vs Neuraxis, Inc. (NRXS)

Genelux Corporation and Neuraxis, Inc. are both Biotechnology companies. Genelux Corporation and Neuraxis, Inc. are of similar size ($88.7M and $86.2M). Genelux Corporation has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Genelux Corporation leads on 7 and Neuraxis, Inc. on 7.

Valuation

Metric GNLX NRXS Biotechnology median
P/E n/m n/m 10.26
P/S 7.24 13.79 9.18
P/B 5.05 10.89 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 6.33 12.23 8.98
Earnings yield (47.51%) (12.89%) (34.89%)
Free cash flow yield (35.25%) (7.88%) (24.52%)

Profitability

Metric GNLX NRXS Biotechnology median
Gross margin (3.42%) 85.56% 65.16%
Operating margin 0.00% (144.51%) 0.00%
Net margin 0.00% (159.01%) 0.00%
Free cash flow margin 0.00% (106.10%) 0.00%
Return on equity (177.93%) (153.96%) (50.12%)
Return on assets (121.80%) (98.96%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNLX NRXS Biotechnology median
Revenue growth (TTM) — 65.22% 6.26%
EPS growth (last fiscal year) 9.47% 22.13% 29.88%
Revenue growth, 5-year CAGR — 13.08% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX NRXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 3.04 4.89
Net debt to EBITDA 0.44 0.64 1.01

Dividend

Metric GNLX NRXS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GNLX NRXS Biotechnology median
Market cap 88.68m 86.15m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack